Status:
COMPLETED
GlyT-1 Inhibitor Treatment for Refractory Schizophrenia
Lead Sponsor:
China Medical University Hospital
Conditions:
Schizophrenia
Treatment Refractory
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The etiology of schizophrenia remains unclear In recent one decade, hypofunction of N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. Hence, enhancing N...
Detailed Description
The etiology of schizophrenia remains unclear. In recent one decade, hypofunction of N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. Hence, enhancing ...
Eligibility Criteria
Inclusion
- Fulfill the criteria of schizophrenia according to the Diagnostic and Statistic Manual, fourth edition (DSM-IV).
- Poor response of clozapine treatment: a 12-week treatment of clozapine without satisfactory response: a severity score of Clinical Global Impression Scale(CGI)\>=4, a total score of Positive and Negative Syndrome Scale(PANSS)\>= 60, and a Scale for the Assessment of Negative Symptoms(SANS)score of \>=40. the doses of clozapine remain stable for at least 12 weeks prior to their enrollment in this proposed study,
- Agree to participate in the study and provide informed consent.
Exclusion
- current substance abuse or history of substance dependence in the past 6 months
- use of depot antipsychotic in the past 6 months
- serious medical or neurological illness
- pregnancy
- inability to follow protocol.
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01251055
Start Date
April 1 2010
End Date
October 1 2013
Last Update
October 29 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan, Taiwan, 400